| Technical Name | A novel pharmacotherapy for neuropsychiatric disorders : alpha6 GABA-A receptor modulators | ||
|---|---|---|---|
| Project Operator | National Taiwan University | ||
| Project Host | 邱麗珠 | ||
| Summary | "The GABAA receptor subtype selectivity is an exclusive property of our compounds. Our compounds are positive allosteric modulators (PAMs) of the α6 subunit-containing GABAA receptors (α6GABAARs). Currently, there is no α6GABAAR-selective drug on the market. Thus, they are first-in-class in terms of treatments of the neuropsychiatric disorderstrigeminal pain mentioned above. Our patent compou |
||
| Scientific Breakthrough | - |
||
| Industrial Applicability | - |
||
| Keyword | |||
| Notes | |||
- Contact
- futuretech.most@gmail.com
other people also saw